Arlington-backed Everest Clinical Research to acquire August Research

August Research is a European contract research organisation.

  • Arlington acquired Everest in 2020
  • Everest is a full-service CRO based in Toronto
  • Arlington is a Washington, DC-based private equity firm

Everest Clinical Research, backed by Arlington Capital Partners, will acquire August Research, a European contract research organisation (CRO).

August provides clinical trial services (CTS) and pharmacovigilance (PV) services to pharmaceutical and biotechnology clients. It is based in Sofia, Bulgaria.

“The acquisition of August is highly strategic for Everest as it further expands our global service offering and establishes a beachhead in one of the largest clinical trial markets in the world,” said Malcolm Little, a partner at Arlington. “With the addition of several European offices to complement Everest’s existing presence in North America and Asia, Everest further engrains itself as a truly global CRO.”

The combination of Everest and August’s capabilities will provide a global, full suite of clinical services to its broad client base, accelerating growth opportunities for the merged company, according to a release.

Dana Leff Niedzielska and Lukasz Niedzielski, August’s founders, alongside other MDs in the local European offices will continue as key executive leaders.

Arlington acquired Everest in 2020.

Everest is a full-service CRO that provides clinical research services to pharmaceutical, biotechnology, and medical device industries. It is based in Toronto, Ontario.

Arlington is a Washington, DC-based private equity firm with around $7 billion in capital commitments. It targets middle market investment opportunities in healthcare, government services and technology, aerospace and defence, and business services and software.

No financial details of the transaction were disclosed.